Zharinov Gennady M, Bogomolov Oleg A, Neklasova Natalia N, Anisimov Vladimir N
Department of Radiotherapy, The Russian Research Center of Radiology and Surgical Technologies, St. Petersburg, Russia.
Department of Carcinogenesis and Oncogerontology, N.N. Petrov Research Institute of Oncology, St. Petersburg, Russia.
Oncoscience. 2017 Feb 24;4(1-2):7-13. doi: 10.18632/oncoscience.337. eCollection 2017 Jan.
Despite the prostate-specific antigen (PSA) serum level commonly uses as tumor marker in diagnosis of prostate cancer, it seems that PSA doubling time (PSADT) could be more useful indicator of tumor behavior and of prognosis for patients. The results of hormone and radiation therapy were evaluated for 912 prostate cancer having at least 2 PSA tests before the treatment was started. Clustering procedure (selection of homogenous group) was performed by using PSADT as the classification marker. The rate of PSADT was estimated for different dissemination rate, age, Gleasons's score and education level. PSADT index inversely correlated with the rate of prostate cancer dissemination, Gleason's score and the level of education were directly correlated with the age of patients. Survival time was longer and PSADT index was higher in "slow" tumor growing subgroups in local, local-advanced and metastatic prostate cancer patients than these in "fast" subgroups. The study confirmed the prognostic value of pretreatment PSADT in prostate cancer patients independently of cancer progression. No significant relationship exists between the authors and the companies/organizations whose products or services may be referenced in this article.
尽管前列腺特异性抗原（PSA）血清水平通常用作前列腺癌诊断中的肿瘤标志物，但PSA倍增时间（PSADT）似乎可能是更有用的肿瘤行为指标及患者预后指标。对912例在开始治疗前至少进行过2次PSA检测的前列腺癌患者的激素和放射治疗结果进行了评估。以PSADT作为分类标志物进行聚类程序（选择同质组）。针对不同的扩散率、年龄、 Gleason评分和教育水平估计PSADT率。PSADT指数与前列腺癌扩散率呈负相关，Gleason评分和教育水平与患者年龄呈正相关。在局部、局部进展和转移性前列腺癌患者中，“缓慢”肿瘤生长亚组的生存时间更长，PSADT指数更高，高于“快速”亚组。该研究证实了治疗前PSADT在前列腺癌患者中的预后价值，与癌症进展无关。本文作者与文中可能引用其产品或服务的公司/组织之间不存在重大关系。
